Research programme: antibody-drug conjugates - LegoChem Biosciences/Novimmune

Drug Profile

Research programme: antibody-drug conjugates - LegoChem Biosciences/Novimmune

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator LegoChem Biosciences; NovImmune SA
  • Class Antineoplastics; Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 13 Feb 2017 Early research in Cancer in Switzerland (Parenteral)
  • 13 Feb 2017 Novimmune and LegoChem Biosciences agree to develop antibody-drug conjugate for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top